Skip to content
10-Q

Quarterly Report

Vera Therapeutics, Inc. VERA

0000950170-25-064733

← back to feed
Filed
May 7, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 63.77M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $50.91M
Long Term Debt Q1 2025 · Dec 31, 2024 $50.69M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $55.09M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $92.65M
Current Liabilities Q1 2025 · Mar 31, 2025 $21.89M
Current Liabilities Q1 2025 · Dec 31, 2024 $25.37M
Total Liabilities Q1 2025 · Mar 31, 2025 $75.17M
Total Liabilities Q1 2025 · Dec 31, 2024 $78.53M
Current Assets Q1 2025 · Mar 31, 2025 $606.08M
Current Assets Q1 2025 · Dec 31, 2024 $651.22M
Total Assets Q1 2025 · Mar 31, 2025 $610.17M
Total Assets Q1 2025 · Dec 31, 2024 $655.68M
Shares Diluted Q1 2025 · Mar 31, 2024 50.97M sh
Capex Q1 2025 · Mar 31, 2024 $0
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$33.83M
Stockholders Equity Q1 2025 · Mar 31, 2024 $353.54M
Stockholders Equity Q1 2025 · Dec 31, 2023 $101.69M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.56
Eps Basic Q1 2025 · Mar 31, 2024 −$0.56
Sga Expense Q1 2025 · Mar 31, 2024 $7.91M
Rd Expense Q1 2025 · Mar 31, 2024 $23.2M
Net Income Q1 2025 · Mar 31, 2024 −$28.38M
Operating Income Q1 2025 · Mar 31, 2024 −$31.11M